 Connection
Heather Fairfield to Multiple Myeloma
This is a "connection" page, showing publications Heather Fairfield has written about Multiple Myeloma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.848 |
|
|
|
-
Fairfield H, Marinac CR, Hamidi H, Knox K, Nestor B, Marques-Mourlet C, Diaz G, Wong CV, Mishra AK, Schimelman A, Qiang YW, Karam M, Farrell M, Jachimowicz E, Stohn JP, Birmann BM, Cornelius P, Reagan MR. Obesity Accelerates Multiple Myeloma Progression in Certain Mouse Models and in Humans. Cancer Prev Res (Phila). 2026 06 01; 19(6):339-352.
Score: 0.735
-
Fairfield H, Reagan MR. Fiber: A New Myeloma Prevention Approach with Abundant Positive Effects. Cancer Discov. 2026 Apr 01; 16(4):623-625.
Score: 0.727
-
Fairfield H, Reagan MR. The hope for targeting fatty acid binding proteins in multiple myeloma. Oncotarget. 2023 06 19; 14:612-613.
Score: 0.599
-
Fairfield H, Dudakovic A, Khatib CM, Farrell M, Costa S, Falank C, Hinge M, Murphy CS, DeMambro V, Pettitt JA, Lary CW, Driscoll HE, McDonald MM, Kassem M, Rosen C, Andersen TL, van Wijnen AJ, Jafari A, Reagan MR. Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype. Cancer Res. 2021 02 01; 81(3):634-647.
Score: 0.501
-
Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016 Jan; 1364:32-51.
Score: 0.357
-
Murphy CS, Fairfield H, DeMambro VE, Fadel S, Gartner CA, Karam M, Potts C, Rodriguez P, Qiang YW, Hamidi H, Guan X, Vary CPH, Reagan MR. Inhibition of acyl-CoA synthetase long-chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction. Mol Oncol. 2025 Jun; 19(6):1687-1706.
Score: 0.167
-
Farrell M, Fairfield H, Karam M, D'Amico A, Murphy CS, Falank C, Pistofidi RS, Cao A, Marinac CR, Dragon JA, McGuinness L, Gartner CG, Iorio RD, Jachimowicz E, DeMambro V, Vary C, Reagan MR. Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signaling. Elife. 2023 03 07; 12.
Score: 0.147
-
Marques-Mourlet C, Di Iorio R, Fairfield H, Reagan MR. Obesity and myeloma: Clinical and mechanistic contributions to disease progression. Front Endocrinol (Lausanne). 2023; 14:1118691.
Score: 0.147
-
Jafari A, Fairfield H, Andersen TL, Reagan MR. Myeloma-bone marrow adipocyte axis in tumour survival and treatment response. Br J Cancer. 2021 09; 125(6):775-777.
Score: 0.129
-
Sarkar S, Chauhan SKS, Daly J, Natoni A, Fairfield H, Henderson R, Nolan E, Swan D, Hu J, Reagan MR, O'Dwyer M. The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide. Cancer Immunol Immunother. 2020 Mar; 69(3):421-434.
Score: 0.118
-
Fairfield H, Falank C, Farrell M, Vary C, Boucher JM, Driscoll H, Liaw L, Rosen CJ, Reagan MR. Development of a 3D bone marrow adipose tissue model. Bone. 2019 01; 118:77-88.
Score: 0.103
-
McDonald MM, Fairfield H, Falank C, Reagan MR. Adipose, Bone, and Myeloma: Contributions from the Microenvironment. Calcif Tissue Int. 2017 05; 100(5):433-448.
Score: 0.092
-
McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood. 2017 06 29; 129(26):3452-3464.
Score: 0.025
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|